{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Fit-takes-2-to-tyk2-1FYXlNWt","width":444,"version":"1.0","type":"rich","title":"It Takes 2 to TYK2 with Dr.Marissa Joseph and Dr.Geeta Yadav PART I","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/77189102-0884-40c9-97e1-c5012f3c7fda/newderm.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/52208f31-f3e8-4f79-ad95-365280b32b2b\" height=\"200\" width=\"100%\" title=\"It Takes 2 to TYK2 with Dr.Marissa Joseph and Dr.Geeta Yadav PART I\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"💡💡💡𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐛𝐞𝐞𝐧 𝐰𝐨𝐧𝐝𝐞𝐫𝐢𝐧𝐠 𝐰𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 #𝐉𝐀𝐊 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 #𝐓𝐘𝐊-𝟐 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧? 𝐀𝐫𝐞𝐧'𝐭 𝐭𝐡𝐞𝐲 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲?\n\n🟢What 𝐝𝐨𝐞𝐬 #TYK-2 #inhibition mean for 𝐭𝐡𝐞 #𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 treatment landscape?\n\n🟢And when do I recommend an i𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐯𝐞𝐫𝐬𝐮𝐬 𝐨𝐫𝐚𝐥 therapy 𝐟𝐨𝐫 𝐦𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭?\n\n🎫 𝗧𝗵𝗶𝘀 𝗺𝗮𝗿𝗸𝘀 𝗮 𝗳𝗶𝗿𝘀𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗦𝗸𝗶𝗻 𝗮𝗻𝗱 𝗝𝗼𝗶𝗻𝘁𝘀 𝗣𝗼𝗱𝗰𝗮𝘀𝘁- 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝘄𝗼 𝗴𝘂𝗲𝘀𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 𝗼𝗻 𝘁𝗵𝗲 𝘀𝗵𝗼𝘄 𝗮𝘁 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝘁𝗶𝗺𝗲!\n\n𝗪𝗲 𝗮𝗿𝗲 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝗹𝗼𝗼𝗸 𝗮𝘁 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗶𝘁’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝘄𝗶𝘁𝗵 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗮 𝗻𝗲𝘄 𝗼𝗿𝗮𝗹 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗮𝗴𝗲𝗻𝘁 𝗰𝗮𝗹𝗹𝗲𝗱 𝗱𝗲𝘂𝗰𝗿𝗮𝘃𝗮𝗰𝗶𝘁𝗶𝗻𝗶𝗯 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗰𝗼𝗻𝗳𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗮 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲.\n\n𝗗𝗼𝗲𝘀 𝗶𝘁 𝗧𝗬𝗞 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗯𝗼𝘅𝗲𝘀? 𝗟𝗲𝘁’𝘀 𝗳𝗶𝗻𝗱 𝗼𝘂𝘁!\n\n🎙️🎙️🎙️ 𝐏𝐚𝐫𝐭 𝐈  with Dr.Geeta Yadav and Dr.Marissa Joseph!\n\nEpisode Learning Objectives\n\nDiscuss patient unmet needs  as well as appropriate assessment strategies to guide treatment decisions for  moderate to severe psoriasis \n​​Apply current evidence as well as shared decision-making to individualize oral and injectable therapy decisions for patients with moderate to severe plaque psoriasis \n Describe the role and pathophysiology of TYK-2 (tyrosine kinase 2)  inhibition in the clinical manifestation of psoriasis\n\n▶️Episode supported by an IME Grant from Bristol Myers Squibb"}